Skip to main content
SpringerLink
Log in

LncRNA LINC01133 Targeting miR-141-5p to Mediate the Progression and Ameliorate Poor Prognosis of Prostate Cancer

  • HUMAN GENETICS
  • Published:
Russian Journal of Genetics Aims and scope Submit manuscript

Abstract

Prostate cancer is a slowly progressive cancer that develops in the epithelial cells of the prostate, which is prone to bone metastasis. In recent years, with the improvement of living conditions and the extension of life expectancy, the incidence of prostate cancer has also increased year by year in China. This study mainly focuses on the regulatory mechanism of lncRNA LINC01133 (LINC01133) in the progression of prostate cancer, providing new possibilities for the development of prognostic pathways for patients. Prostate cancer patients were diagnosed according to the magnetic resonance imaging (MRI). LINC01133 level was determined by RT-qPCR assays. The clinical significance and prognostic value of LINC01133 in prostate cancer were assessed through the chi-square analysis, Kaplan-Meier curves, and multivariate Cox regression analysis. In vitro cell experiments were performed by CCK-8 and Transwell methods. Luciferase activity assay and Pearson analysis were used to explain the relationship between LINC01133 and miR-141-5p. LINC01133 was decreased in prostate cancer tissue and cell specimens, which was associated with shorter overall survival. The abnormally high expression of LINC01133 directly targeted miR-141-5p and affected the normal growth and behavior of prostate cancer cells, while miR-141-5p mimic alleviated the inhibitory ability of LINC01133 on prostate cancer cells. LINC01133 sponge miR-141-5p mediated the progression of prostate cancer, and LINC01133 may be a potential prognostic marker for prostate cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.
Fig. 5.

REFERENCES

  1. Wang, K.Y., Wang, K.J., and Ma, Q., The expression and significance of p4E-BP1/4E-BP1 in prostate cancer, J. Clin. Lab. Anal., 2022, vol. 36, no. 4, p. e24332.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Sung, H., Ferlay, J., Siegel, R.L., et al., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 2021, vol. 71, no. 3, pp. 209—249.

    Article  PubMed  Google Scholar 

  3. Okidi, R., Opira, C., Sambo, V.D.C., et al., Prostate hyperplasia in St Mary’s Hospital Lacor: utility of prostate specific antigen in screening for prostate malignancy, Afr. Health Sci., 2020, vol. 20, no. 3, pp. 1259—1263.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Ried, K., Tamanna, T., Matthews, S., et al., New screening test improves detection of prostate cancer using circulating tumor cells and prostate-specific markers, Front. Oncol., 2020, vol. 10, p. 582.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Jomoto, W., Tanooka, M., Doi, H., et al., Development of a three-dimensional surgical navigation system with magnetic resonance angiography and a three-dimensional printer for robot-assisted radical prostatectomy, Cureus., 2018, vol. 10, no. 1, p. e2018.

    PubMed  PubMed Central  Google Scholar 

  6. Madkour, M.M., Ramadan, W.S., Saleh, E., and El-Awady, R., Epigenetic modulations in cancer: predictive biomarkers and potential targets for overcoming the resistance to topoisomerase I inhibitors, Ann. Med., 2023, vol. 55, no. 1, p. 2203946.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Ono, K., Horie, T., Baba, O., et al., Functional non-coding RNAs in vascular diseases, FEB. J., 2021, vol. 288, no. 22, pp. 6315—6330.

  8. Hu, C.Y., Wu, K.Y., Lin, T.Y., and Chen, C.C., The crosstalk of long non-coding RNA and microRNA in castration-resistant and neuroendocrine prostate cancer: their interaction and clinical importance, Int. J. Mol. Sci., 2021, vol. 23, no. 1, pp. 1—17.

    Article  Google Scholar 

  9. Song, Z., Zhang, X., Lin, Y., et al., LINC01133 inhibits breast cancer invasion and metastasis by negatively regulating SOX4 expression through EZH2, J. Cell. Mol. Med., 2019, vol. 23, no. 11, pp. 7554—7565.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Ghafouri-Fard, S., Khoshbakht, T., Hussen, B.M., et al., A review on the role of LINC01133 in cancers, Cancer. Cell. Int., 2022, vol. 22, no. 1, p. 270.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Foroughi, K., Amini, M., Atashi, A., et al., Tissue-specific down-regulation of the long non- coding RNAs PCAT18 and LINC01133 in gastric cancer development, Int. J. Mol. Sci., 2018, vol. 19, no. 12, pp. 1—14.

    Article  Google Scholar 

  12. Wollersheim, B.M., van Eenbergen, M., van Asselt, K.M., et al., Type of treatment, symptoms and patient satisfaction play an important role in primary care contact during prostate cancer follow-up: results from the population-based PROFILES registry, BMC Fam. Pract., 2021, vol. 22, no. 1, p. 218.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Zhang, Y., Guo, S., Wang, S., et al., LncRNA OIP5-AS1 inhibits ferroptosis in prostate cancer with long-term cadmium exposure through miR-128-3p/SLC7A11 signaling, Ecotoxicol. Environ. Saf., 2021, vol. 220, p. 112376.

    Article  PubMed  CAS  Google Scholar 

  14. Liang, D., Tian, C., and Zhang, X., LncRNA MNX1‑AS1 promotes prostate cancer progression through regulating miR‑2113/MDM2 axis, Mol. Med. Rep., 2022, vol. 26, no. 1, pp. 1—10.

    Article  Google Scholar 

  15. Hu, R., Wu, P. and Liu, J., LncRNA MAGI2-AS3 inhibits prostate cancer progression by targeting the miR-142-3p, Horm. Metab. Res., 2022, vol. 54, no. 11, pp. 754—759.

    Article  PubMed  CAS  Google Scholar 

  16. Zhang, J.H., Li, A.Y., and Wei, N., Downregulation of long non-coding RNA LINC01133 is predictive of poor prognosis in colorectal cancer patients, Eur. Rev. Med. Pharmacol. Sci., 2017, vol. 21, no. 9, pp. 2103—2107.

    PubMed  Google Scholar 

  17. Yang, G., Li, T., Liu, J., et al., LncRNA MAGI2-AS3 suppresses castration-resistant prostate cancer proliferation and migration via the miR-106a-5p/RAB31 axis, Genomics, 2023, vol. 115, no. 2, p. 110599.

    Article  PubMed  CAS  Google Scholar 

  18. He, L., Chang, H., Qi, Y., et al., ceRNA networks: the backbone role in neoadjuvant chemoradiotherapy resistance/sensitivity of locally advanced rectal cancer, Technol. Cancer Res. Treat., 2021, vol. 20, p. 15330338211062313.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Gong, Q., Hu, Z., Jin, Q., et al., Identification of JPX-RABEP1 pair as an immune-related biomarker and therapeutic target in pulmonary arterial hypertension by bioinformatics and experimental analyses, Int. J. Mol. Sci., 2022, vol. 23, no. 24, p. 15559.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. Ni, Z., Shen, Y., Wang, W., et al., miR-141-5p affects the cell proliferation and apoptosis by targeting BTG1 in cervical cancer, Cancer. Biother. Radiopharm., 2021.https://doi.org/10.1089/cbr.2021.0227

  21. Sommerova, L., Anton, M., Bouchalova, P., et al., The role of miR-409-3p in regulation of HPV16/18-E6 mRNA in human cervical high-grade squamous intraepithelial lesions, Antiviral. Res., 2019, vol. 163, pp. 185—192.

    Article  PubMed  CAS  Google Scholar 

  22. Li, W., Dong, Y., Wang, K.J., et al., Plasma exosomal miR-125a-5p and miR-141-5p as non-invasive biomarkers for prostate cancer, Neoplasma, 2020, vol. 67, no. 6, pp. 1314—1318.

    Article  PubMed  CAS  Google Scholar 

  23. Ambrozkiewicz, F., Karczmarski, J., Kulecka, M., et al., Challenges in cancer biomarker discovery exemplified by the identification of diagnostic microRNAs in prostate tissues, Biomed. Res. Int., 2020, vol. 2020, p. 9086829.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

The authors did not receive support from any organization for the submitted work.

Author information

Authors and Affiliations

  1. Department of Radiology, Wuhan Fourth Hospital, 430000, Wuhan, Hubei, China

    Y. Y. Li & Y. N. Zhang

Authors
  1. Y. Y. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y. N. Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y. N. Zhang.

Ethics declarations

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

The study was conducted with the approval of the Wuhan Fourth Hospital’s ethics committee. The procedures used in this study adhere to the tenets of the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study. The study was conducted with the approval of the hospital’s ethics committee, the related protocols were signed with the patients.

CONFLICT OF INTEREST

The authors of this work declare that they have no conflicts of interest.

CONSENT TO PUBLISH

Not applicable.

Additional information

Publisher’s Note.

Pleiades Publishing remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, Y.Y., Zhang, Y.N. LncRNA LINC01133 Targeting miR-141-5p to Mediate the Progression and Ameliorate Poor Prognosis of Prostate Cancer. Russ J Genet 59 (Suppl 2), S191–S198 (2023). https://doi.org/10.1134/S1022795423140077

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S1022795423140077

Keywords:

Search

Navigation